Priority,Rule
Relevant Abstracts,All abstracts that coincides with disease area of interest (IgAN)  ​
Internal,Calliditas sponsored studies
Very High,Assigned by the Calliditas team  ​
High,"All relevant abstracts that include any of the following: Phase 2/3 data (including meta-analyses), real-world data (including patient reported outcomes, retrospective analyses and registry data)   ​"
Medium​,"All relevant abstracts that include any of the following: Phase 1 data, general HEOR studies, prognostic studies, preclinical studies, other general studies   ​"
Low,All relevant abstracts that only have mention of an indication of interest and does not include any other data  ​